In this dataset we provide the 1000 Genomes Project's samples processed in our manuscript: Cortes-Figueiredo, F.; Carvalho, F.S.; Fonseca, A.C.; Paul, F.; Ferro, J.M.; Sch��nherr, S.; Weissensteiner, H.; Morais, V.A. From Forensics to Clinical Research: Expanding the Variant Calling Pipeline for the Precision ID mtDNA Whole Genome Panel. Int. J. Mol. Sci. 2021, 22, 12031. https://doi.org/10.3390/ijms222112031. Abstract Despite a multitude of methods for the sample preparation, sequencing, and data analysis of mitochondrial DNA (mtDNA), the demand for innovation remains, particularly in comparison with nuclear DNA (nDNA) research. The Applied Biosystems��� Precision ID mtDNA Whole Genome Panel (Thermo Fisher Scientific, USA) is an innovative library preparation kit suitable for degraded samples and low DNA input. However, its bioinformatic processing occurs in the enterprise Ion Torrent Suite��� Software (TSS), yielding BAM files aligned to an unorthodox version of the revised Cambridge Reference Sequence (rCRS), with a heteroplasmy threshold level of 10%. Here, we present an alternative customizable pipeline, the PrecisionCallerPipeline (PCP), for processing samples with the correct rCRS output after Ion Torrent sequencing with the Precision ID library kit. Using 18 samples (3 original samples and 15 mixtures) derived from the 1000 Genomes Project, we achieved overall improved performance metrics in comparison with the proprietary TSS, with optimal performance at a 2.5% heteroplasmy threshold. We further validated our findings with 50 samples from an ongoing independent cohort of stroke patients, with PCP finding 98.31% of TSS���s variants (TSS found 57.92% of PCP���s variants), with a significant correlation between the variant levels of variants found with both pipelines. Please refer to our the github page filcfig/PCP, for more details on running the PrecisionCalllerPipeline.

This research was funded by Funda����o para a Ci��ncia e Tecnologia (FCT) (FCT/PTDC/MED-NEU/7976/2020), and a project cofunded by FEDER (POR Lisboa 2020���Programa Operacional Regional de Lisboa PORTUGAL 2020), and FCT (PAC-PRECISE LISBOA-01-0145-FEDER-016394), and the National Multiple Sclerosis Society (NMSS), NMSS Pilot Research Grant (PP-1712-29466). F.C.F.'s stipend was supported by FCT (PD/BD/114122/2015), and by Merck Germany (restricted research grant). V.A.M. is an iFCT researcher (IF/01693/2014; IMM/CT/27-2020).